AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

Epi Biologics announced it raised $73.1 Million in an amended filing from an offering of $73.1 Million

Apr 25, 2024•over 1 year ago

Amount Raised

$73.1 Million

San MateoBiotechnology

Company Information

Company

EpiBiologics

Location

1900 Alameda de las Pulgas

San Mateo, California, United States

About

EpiBiologics is building a next-generation protein degradation platform that targets membrane and extracellular proteins. EpiBiologics was founded in 2022 based on the pioneering work from academic founder Dr. Jim Wells of the University of California San Francisco (UCSF). The Company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner. Headquartered in San Mateo, EpiBiologics is backed by leading healthcare investors and aims to develop first-in-class and best-in-class targeted therapies across multiple therapeutic areas.

Company News

(6 articles)

Mon, 28 Apr 2025 07:00:00 GMT

EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody - Business Wire

Thu, 20 Jul 2023 07:00:00 GMT

EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million - BioSpace

Mon, 04 Nov 2024 08:00:00 GMT

EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings - Business Wire

Wed, 22 Mar 2023 07:00:00 GMT

Targeting the destruction of proteins, Peninsula biotech EpiBiologics raises $50M - The Business Journals

Wed, 22 Mar 2023 07:00:00 GMT

EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform - Business Wire

Thu, 05 Oct 2023 07:00:00 GMT

Influential Women 2023: Ann Lee-Karlon, CEO and President, EpiBiologics - The Business Journals

FundzWatch™ Score

Medium Activity

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech